Long-term use of fondaparinux in major orthopedic surgery
Küçük Resim Yok
Tarih
2012
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Turkish Joint Diseases Foundation
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Amaç: Majör ortopedik cerrahi sonrasında uzun süreli fondaparinuks sodyum kullanımının majör kanmaya yol açıp açmadığı araştırıldı. Hastalar ve yöntemler: Majör ortopedik ameliyat planlanan 18 yaşından büyük 43 hasta (30 kadın, 13 erkek; ort. yaş 66 yıl; dağılım 34-94 yıl) çalışmaya alındı. Total kalça protezi, total diz protezi ve proksimal femur uç kırığı ameliyatları majör ortopedik ameliyatlar olarak belirlendi. Profilaksi için günde bir kez 2.5 mg fondaparinuks sodyum, subkütan olarak uygulandı. Cerrahi kesi kapatıldıktan 6-8 saat sonra ilk doz profilaksi başlandı. Profilaksi süresince (31±3 gün) hastalarda semptomatik derin ven trombozu takibi yapıldı. Ameliyat öncesi ve ameliyat sonrası birinci haftada ve birinci ayda serum kreatinin, trombosit ve hemoglobin düzeyleri ölçüldü. Yara iyileşme süreleri ve iyileşme komplikasyonları ve profilaksi süresince görülen majör-minör kanamalar kaydedildi. Bulgular: Takipler süresince hiçbir hastada semptomatik derin ven trombozu veya semptomatik pulmoner emboli saptanmadı. Hastaların ikisinde (%4.6) yara iyileşmesi gecikmesi, dördünde (%9.3) minör ekimoz gelişti. Hiçbir hastada majör kanama görülmedi. Sonuç: Fondaparinuksun uzun süreli kullanımına bağlı olarak majör kanama komplikasyonu gözlenmedi. Ancak fondaparinuks preparatının uzun süreli kullanımda etkilerini ortaya koymak için daha geniş ve kontrol grubu ile yapılan çalışmalara gereksinim vardır.
Objectives: This study aims to investigate whether the usage of fondaparinux sodium may result in major hemorrhages following major orthopedic surgery. Patients and methods: Forty-three patients (30 females and 13 males; mean age 66 years; range 34 to 94 years) at the age of >18 years who were scheduled for major orthopedic surgery were included. Total hip arthroplasty, total knee arthroplasty and proximal femur fracture surgeries were defined as the major orthopedic surgeries. Prophylaxis was administered with 2.5 mg fondaparinux sodium once daily subcutaneously. Prophylaxis was initiated at 6-8 hours after the closure of incision. During the prophylaxis period (31±3 days), the patients were monitored for symptomatic deep venous thrombosis. Serum creatinine, platelet and hemoglobin levels were measured at the baseline and in the first week and at one month postoperatively. Wound healing time, healing complications, and major/minor hemorrhages seen during the prophylaxis period were recorded. Results: During the follow-up, none of the patients had symptomatic deep vein thrombosis or symptomatic pulmonary embolism. Two patients (4.6%) had delayed wound healing, while four (9.3%) had minor ecchymosis. No major hemorrhages were observed in any patients. Conclusion: With the long-term use of fondaparinux, we did not observe any major hemorrhagic complications. However, further large-scale studies including control groups are required to establish the effects of long-term use of fondaparinux.
Objectives: This study aims to investigate whether the usage of fondaparinux sodium may result in major hemorrhages following major orthopedic surgery. Patients and methods: Forty-three patients (30 females and 13 males; mean age 66 years; range 34 to 94 years) at the age of >18 years who were scheduled for major orthopedic surgery were included. Total hip arthroplasty, total knee arthroplasty and proximal femur fracture surgeries were defined as the major orthopedic surgeries. Prophylaxis was administered with 2.5 mg fondaparinux sodium once daily subcutaneously. Prophylaxis was initiated at 6-8 hours after the closure of incision. During the prophylaxis period (31±3 days), the patients were monitored for symptomatic deep venous thrombosis. Serum creatinine, platelet and hemoglobin levels were measured at the baseline and in the first week and at one month postoperatively. Wound healing time, healing complications, and major/minor hemorrhages seen during the prophylaxis period were recorded. Results: During the follow-up, none of the patients had symptomatic deep vein thrombosis or symptomatic pulmonary embolism. Two patients (4.6%) had delayed wound healing, while four (9.3%) had minor ecchymosis. No major hemorrhages were observed in any patients. Conclusion: With the long-term use of fondaparinux, we did not observe any major hemorrhagic complications. However, further large-scale studies including control groups are required to establish the effects of long-term use of fondaparinux.
Açıklama
Anahtar Kelimeler
Artroplasti, artroplasti/replasman/diz, artroplasti/replasman/kalça, fondaparinuks, kalça kırığı, ortopedik cerrahi, ortopedik, Artr venöz tromboz, Arthroplasty, arthroplasty/replacement/hip, arthroplasty/ replacement/knee, fondaparinux, hip fractures, orthopedic surgery, orthopedics, venous thrombosis
Kaynak
Eklem Hastalıkları ve Cerrahisi
WoS Q Değeri
Scopus Q Değeri
Q2
Cilt
23
Sayı
3
Künye
Altıntaş, F., Uluçay, Ç., Üğütmen, E. vd. (2012). Long-term use of fondaparinux in major orthopedic surgery. Eklem Hastalıkları ve Cerrahisi, Turkish Joint Diseases Foundation. 23(3), s. 168-172.
